Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesOphthalmology/OptometryAetna artificial retina iris Coverage Update | Ope…
    Ask Trek AI about this page
    CurrentAetnaPolicy 0713

    Artificial Retina and Artificial Iris

    Customize your policy alerts

    Sign up for Aetna Policy 0713 alerts

    Get alerted when Policy 0713 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage of artificial retina (retinal prosthesis) and artificial iris devices for Aetna members, defining these interventions as experimental and investigational due to insufficient evidence of safety and effectiveness.

    Policy Summary
    PayerAetna
    PolicyArtificial Retina and Artificial Iris
    Policy CodePolicy 0713
    Change TypeNo material clinical or coverage changes in this revision
    Effective DateSep 30, 2005
    Last ReviewOct 17, 2023
    Next Review DateAug 8, 2024
    Key ActionWhen requesting coverage exceptions, provide documentation of the implanted device, laterality, objective visual function test results, perioperative and long-term complications, and follow-up duration.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    30subjects in pivotal Argus II trial
    60electrodes in Argus II
    3 yrsreported follow-up
    over 100Argus II implanted worldwide
    8.8%glaucoma rate after iris implant
    79%eyes explanted after cosmetic iris complications

    Coverage Criteria

    Experimental and Investigational

    Aetna considers the following interventions experimental and investigational because effectiveness has not been established:

    Artificial retina devices (e.g., the Argus II) are considered experimental and investigational because there is insufficient scientific evidence of the safety and effectiveness of these devices in restoring vision.

    [[chunk 3]]

    Artificial iris devices (e.g., the CustomFlex Artificial Iris) for anterior segment reconstruction and the treatment of aniridia, post‑operative or traumatic aphakia, and other iris defects are considered experimental and investigational because there is insufficient scientific evidence of their safety and effectiveness.

    [[chunk 3]]

    Clinical candidate and outcome summaries

    Clinical findings and selection considerations reported

    Argus II candidate considerations: Candidates typically have end‑stage outer retinal disease (e.g., retinitis pigmentosa) with profound vision loss; implantation is typically in the worse‑seeing eye with the patient using a glasses‑mounted camera and external processor. Preoperative assessment and intensive post‑implant rehabilitation are required; outcomes are variable but reported improvements include orientation/mobility, target localization, and certain visual function tests, with substantial variability across patients.

    Based on multi‑center trial data and reviews (see chunks 22, 25).

    Artificial iris candidate considerations: Indications reported include congenital, traumatic, or iatrogenic aniridia and other significant iris defects; candidate evaluation should include assessment of residual iris tissue, consideration of aphakia or need for IOL correction, and device selection given differences in design (embedded fiber mesh associated with higher complication rates).

    Based on retrospective series and device reviews (see chunks 36, 37).

    Coverage considerations and clinical criteria

    Evidence‑based considerations and observed outcomes informing coverage decisions

    Indication and device: Patients with congenital, traumatic, or iatrogenic aniridia or other significant iris defects may be considered for artificial iris implantation in clinical reports; the CustomFlex (HumanOptics) device is described in series and is FDA‑approved in some contexts, but overall evidence on safety and effectiveness is limited and heterogeneous.

    Supported by retrospective series and device descriptions (chunks 36, 38).

    Implantation techniques: Reported implantation methods include endocapsular placement, ciliary sulcus implantation, scleral fixation, and composite IOL‑iris constructs; endocapsular implantation in reported series was associated with fewer severe post‑operative complications and high patient satisfaction.

    See chunks 37, 48.

    Risk considerations: Complications reported across series include elevated intraocular pressure/glaucoma, corneal edema, intraocular inflammation, iris retraction syndrome, vaulting requiring revision, graft failure, need for consecutive anterior segment surgery or explantation; cosmetic (elective) iris implants have particularly high complication and explantation rates.

    Use of the CPT and HCPCS codes listed in this policy for the indications addressed in this Clinical Policy Bulletin is not covered. The policy explicitly identifies specific procedure codes for retinal prosthesis placement and follow-up programming (e.g., 0100T, 0472T, 0473T) and codes for insertion of iris prostheses (e.g., 0616T, 0617T, 0618T) as well as HCPCS codes for artificial iris and retinal prosthesis components (e.g., C1839, C1841, C1842, L8608) as not covered for the indications in this CPB.

    Reported case series associate implants that contain an embedded fiber mesh with higher rates of complications such as glaucoma, darkening of iris tissue, and need for additional anterior segment surgery. The policy notes that use of full iris prostheses without embedded fiber mesh, and in some cases slightly smaller-than-recommended implant sizing, may reduce these device-specific risks and therefore may be preferred when reconstructing the anterior segment.

    Cosmetic iris implantation devices marketed for elective eye color change (examples include NewColorIris and BrightOcular) have been associated with serious, sight‑threatening complications in clinical reports. In a retrospective series of patients who presented after cosmetic implants, common findings included iris abnormalities, elevated intraocular pressure, corneal edema, intraocular inflammation and cataract; many eyes required surgical interventions including explantation, corneal transplantation and glaucoma surgery.

    Aetna considers artificial retina devices (e.g., the Argus II) and artificial iris devices (e.g., the CustomFlex Artificial Iris) to be experimental and investigational for the clinical indications addressed in this CPB because the effectiveness and safety of these approaches have not been established in the peer‑reviewed evidence. Services for interventions classified as experimental and investigational may be denied as not medically necessary.

    Clinical reports indicate that the Argus II prosthesis does not consistently provide sufficiently reliable visual information to improve performance on certain navigational precision tasks that rely on non‑visual senses. In a small study, implanted patients did not show the same improvements in path reproduction precision as controls and, for some tasks, showed limited benefit from the prosthesis compared with non‑visual navigation strategies.

    Elective cosmetic iris implants placed solely for cosmetic eye‑color modification have high complication and explantation rates in reported series. In the cited retrospective review, a large proportion of implanted eyes subsequently underwent cosmetic iris removal (explantation) and many required additional surgical procedures (for example, corneal transplantation, cataract extraction and glaucoma surgery), supporting classification of these elective cosmetic implants as associated with substantial post‑operative morbidity.

    Coding

    CPT codes not covered for indications listed in the CPBCPTNot Covered
    0100TPlacement of a subconjunctival retinal prosthesis receiver and pulse generator, and implantation of intra-ocular retinal electrode array, with vitrectomy.
    0472TDevice evaluation, interrogation, and initial programming of intra-ocular retinal electrode array (eg, retinal prosthesis), in person, with iterative adjustment of the implantable device to test functionality, select optimal permanent programmed values with analysis, including visual training, with review and report by a qualified health care professional.
    0473TDevice evaluation and interrogation of intra-ocular retinal electrode array (eg, retinal prosthesis), in person, including reprogramming and visual training, when performed, with review and report by a qualified health care professional.
    0616TInsertion of iris prosthesis, including suture fixation and repair or removal of iris, when performed; without removal of crystalline lens or intraocular lens, without insertion of intraocular lens.
    0617TInsertion of iris prosthesis with removal of crystalline lens and insertion of intraocular lens.
    0618TInsertion of iris prosthesis with secondary intraocular lens placement or intraocular lens exchange.
    HCPCS codes not covered for indications listed in the CPBHCPCSNot Covered
    C1839Iris prosthesis [artificial iris devices].
    C1841Retinal prosthesis, includes all internal and external components.
    C1842Retinal prosthesis, includes all internal and external components; add-on to C1841.
    L8608Miscellaneous external component, supply or accessory for use with the argus ii retinal prosthesis system.
    ICD-10 codes referenced in CPBICD-10
    E08.311-E08.39Diabetes mellitus due to underlying condition with ophthalmic complications [retinopathy].
    E09.311-E09.39Drug or chemical induced diabetes mellitus with ophthalmic complications [retinopathy].
    E10.311-E10.39Type 1 diabetes mellitus with ophthalmic complications [retinopathy].
    E11.311-E11.39Type 2 diabetes mellitus with ophthalmic complications [retinopathy].
    E13.311-E13.39Other specified diabetes mellitus with ophthalmic complications [retinopathy].
    H21.00-H21.9Other disorders of iris and ciliary body.
    H27.00-H27.03Aphakia [Post-operative or traumatic aphakia].
    H31.101-H31.129Choroidal degeneration.
    H33.001-H35.9Retinal detachments and breaks, retinal vascular occlusions and other retinal disorders.
    Q13.0Coloboma of iris.
    1–10 of 13
    1/2
    Visual acuity recorded in trials
    Best-recorded visual acuity (Argus II trials)20/1,260
    Trial population size (pivotal study)30 subjects enrolled; follow-up up to 2.7 years
    Performance outcomes (system on vs off)Improved object localization (96% of subjects), motion discrimination (57%), oriented grating discrimination (23%)

    Provider Actions and Requirements

    Billing Rule

    Codes explicitly listed as not covered

    Use the following CPT and HCPCS codes exactly as listed when submitting claims: 0100T, 0472T, 0473T, 0616T, 0617T, 0618T, C1839, C1841, C1842, L8608. These codes are identified in the policy as not covered for the indications in this Clinical Policy Bulletin and should not be billed for covered indications under this CPB.

    • CPT: 0100T, 0472T, 0473T, 0616T, 0617T, 0618T
    • HCPCS: C1839, C1841, C1842, L8608
    Prior Authorization

    Prior authorization: document candidacy, rehab, counseling, team assessment

    Obtain pre-authorization when requesting coverage or exception review, and include documentation that the patient meets candidacy criteria, has completed or been assessed for prior rehabilitation, received expectations counseling, and underwent multidisciplinary evaluation. The policy recommends these elements to support any coverage exception requests for specialized device procedures.

    Background

    Retinal prostheses are implantable systems intended to restore some visual perception by electrically stimulating surviving retinal neurons in degenerative outer retinal diseases (for example, retinitis pigmentosa). Systems are typically epiretinal (positioned on the retinal surface and driven by an external camera) or subretinal (positioned behind the retina to convert light to electrical signals). The Argus II is an epiretinal system that uses a glasses‑mounted camera to deliver stimulation via a 60‑electrode array; clinical evidence consists primarily of small feasibility and single‑arm series with variable functional improvements and documented device‑ or surgery‑related adverse events.

    Definitions

    Epiretinal implant — definition and mechanism
    DefinitionAn implant positioned on the retinal surface that receives light signals from an external camera system and stimulates retinal neurons via an electrode array.
    MechanismExternal camera captures images transmitted to implanted electronics which decode signals and deliver electrical stimulation to retinal ganglion and bipolar cells via an electrode array.
    Typical componentsGlasses-mounted camera, video processing unit (VPU), telemetry/power system, implanted stimulator and electrode array on the retinal surface.
    Subretinal implant — definition
    DefinitionAn implant positioned behind the retina that converts incoming light directly into electrical signals to stimulate remnant retinal cell layers.
    Mechanism
    Policy Summary
    PayerAetna
    PolicyArtificial Retina and Artificial Iris
    Policy CodePolicy 0713
    Change TypeNo material clinical or coverage changes in this revision
    Effective DateSep 30, 2005
    Last ReviewOct 17, 2023
    Next Review DateAug 8, 2024
    Key ActionWhen requesting coverage exceptions, provide documentation of the implanted device, laterality, objective visual function test results, perioperative and long-term complications, and follow-up duration.
    SourceLink
    On This Page
    Coverage CriteriaCodingProvider Actions and RequirementsBackgroundDefinitions

    See chunks 36, 41, 45, 48.

    Informed consent and counseling: Patients should be counseled about limited high‑quality evidence, variable complication rates related to device design and implantation technique, the potential need for additional surgeries including explantation, and realistic functional and cosmetic expectations prior to implantation.

    Consistent with observed outcomes and device‑specific cautions (chunks 36, 37, 45, 48).

    • Document candidacy criteria and prior rehabilitation
    • Include expectations counseling and multidisciplinary team assessment
    Prior Authorization

    Prior authorization: indicate FDA‑approved CustomFlex device

    When seeking approval for an FDA‑approved CustomFlex Artificial Iris, note device regulatory status and supply documentation that the CustomFlex device is the implanted prosthesis versus non‑marketed or cosmetic implants. The policy distinguishes FDA‑approved CustomFlex from investigational devices and advises noting FDA-approved device use in authorization requests.

    • Indicate that CustomFlex Artificial Iris (FDA‑approved) is used
    • Differentiate FDA‑approved device from investigational or cosmetic implants
    Note

    Prior authorization: no PA requirement specified in this extract

    No specific routine prior authorization form or requirement is listed in this extract; providers should follow standard plan processes but recognize the policy does not specify an automatic PA pathway in these sections.

    Note
    Step Therapy

    Selection: confirm indication and assess alternatives before implantation

    Confirm that the patient has end‑stage outer retinal disease (e.g., retinitis pigmentosa) for retinal prosthesis candidates or a clinically significant iris defect (congenital, traumatic, iatrogenic) for artificial iris candidates, and assess alternative, less-invasive options prior to implant consideration.

    • For Argus II candidates: confirm end‑stage outer retinal disease and profound vision loss
    • For artificial iris candidates: document indication (congenital, traumatic, iatrogenic) and remnant iris status
    Step Therapy

    Conservative alternatives: document failure/intolerance of non‑surgical options

    Before implantation, document trial and failure or intolerance of conservative alternatives when appropriate — for example, colored contact lenses, corneal tattooing, or prosthetic contact options — and record why these measures are unsuitable or unsuccessful for the patient.

    • Document use and failure/intolerance of colored contact lenses
    • Document consideration and unsuitability of corneal tattooing or prosthetic contact options
    Note
    Documentation Required

    Supporting documentation: supply clinical trial reports and outcome data

    Provide supporting clinical trial reports and outcome data when requesting coverage exceptions; the policy background documents trial enrollment, visual function tests, and adverse events that support evaluation of medical necessity.

    • Include relevant clinical trial reports and objective visual function test results (mobility, localization, grating VA, Goldmann field)
    • Report trial enrollment and follow‑up duration as applicable
    Documentation Required

    Required clinical documentation: device, laterality, complications, objective outcomes

    Include detailed clinical documentation with any request: identify the device implanted, laterality, perioperative and long‑term complications, objective visual function test results (e.g., mobility, localization, grating visual acuity, Goldmann field), and follow‑up duration to support assessment of outcomes and necessity.

    • Device model and laterality
    • Perioperative and long‑term complications and interventions
    • Objective visual function test results and follow‑up duration
    Documentation Required

    Required clinical documentation: indications, ocular history, surgical technique, follow‑up

    Document specific clinical indications and prior ocular history in the medical record, including congenital or traumatic aniridia, iris melanotic lesion excision, Urrets‑Zavalia syndrome, aphakia, and relevant comorbidities; also detail surgical technique (endocapsular, sulcus, scleral fixation) and follow‑up findings (BCVA, IOP, complications, patient satisfaction).

    • Indication (congenital, traumatic, iatrogenic) and prior ocular comorbidities
    • Surgical technique and post‑operative findings including BCVA and IOP
    Note

    Policy history and notices: extract includes review history but not additional documentation lists

    This policy extract includes policy history and boilerplate notices; it does not substitute for submitting required clinical documentation with any authorization or exception request — providers should still follow the documentation guidance in the policy when requesting coverage.

    Denial Risk

    Denial risk: experimental and investigational interventions may be denied

    Interventions classified as experimental and investigational (artificial retina devices such as Argus II and artificial iris devices such as CustomFlex for the listed indications) are not considered established; services for these interventions may be denied as not medically necessary.

    Documentation Required

    Adverse event reporting: fully document serious device‑ or surgery‑related AEs

    Report and document serious device‑ or surgery‑related adverse events thoroughly; the Argus II trial reported 11 subjects with 23 serious device‑ or surgery‑related adverse events, and inadequate AE reporting or lacking complication details could jeopardize claims or exception requests.

    • Include full details of any serious adverse events and their management
    • Attach treatment records showing resolution or ongoing care for AEs
    Denial Risk

    Complication‑related utilization risk: prior cosmetic implant complications often require explantation and further surgery

    Recognize heightened utilization and reoperation risk after complications from cosmetic artificial iris implants; the policy documents frequent serious complications (elevated IOP, corneal edema, inflammation) that often required explantation and additional surgeries and may trigger high‑level review for subsequent utilization.

    • Document any prior cosmetic iris implantation and subsequent complications or explantation
    • Expect potential denial or additional review for procedures related to prior device complications
    Denial Risk

    Not applicable / cosmetic implants: elective cosmetic iris implants associated with high complication and explantation rates

    Document that conservative, non‑marketed cosmetic iris implants are associated with high complication and explantation rates; the policy highlights that elective cosmetic iris implants lack supportive safety evidence and often required removal and further interventions.

    Receives light from the environment and transduces it into electrical stimulation of photoreceptor-layer replacements or remnant cells.
    RequirementRequires intact optic nerve pathway to transmit elicited retinal responses to the cortex.
    Humanitarian Device Exemption (HDE)
    DefinitionAn FDA regulatory pathway that allows marketing approval for devices intended to treat or diagnose diseases affecting fewer than 8,000 individuals per year in the U.S., with exemption from a full review of clinical effectiveness.
    Argus II contextArgus II was approved by the FDA under a Humanitarian Device Exemption (HDE) on February 14, 2013.
    Regulatory implicationHDE approval indicates the FDA concluded probable benefit outweighed risks for a small population but exempts the device from demonstration of full clinical effectiveness.
    Argus II Retinal Prosthesis System — device description
    Device descriptionEpiretinal prosthesis that converts video images from a glasses-mounted camera into stimulation patterns sent wirelessly to a microelectrode array on the retina (60-electrode array in Argus II).
    ComponentsGlasses-mounted camera and transmitter, video processing unit (VPU), telemetry system, implanted stimulator and intraocular electrode array secured to the retina.
    Clinical contextDesigned for patients with profound vision loss from end-stage outer retinal disease (predominantly retinitis pigmentosa); over 100 devices implanted worldwide as reported.
    Aniridia — definition
    DefinitionPartial or total absence of the iris, congenital or traumatic in origin, leading to light sensitivity and glare disability.
    EpidemiologyCongenital aniridia is rare, affecting approximately 1 in 50,000 to 100,000 individuals in the U.S.
    Clinical consequenceLoss of iris function increases light sensitivity and may cause significant visual disturbances warranting reconstructive options.
    Custom artificial iris (HumanOptics CustomFlex) — definition and implantation options
    Device definitionA flexible, custom-made artificial iris prosthesis (HumanOptics CustomFlex) used to reconstruct the anterior segment and treat aniridia or other iris defects.
    Implantation optionsCan be implanted within the capsular bag (endocapsular), in the ciliary sulcus, or with scleral fixation; may be used with or without embedded fiber mesh and combined with intraocular lens procedures as needed.
    Clinical findingsSeries report improved cosmetic appearance and visual function but implants with embedded fiber mesh were associated with higher rates of glaucoma and reoperation.
    CustomFlex Artificial Iris — FDA-approved device description
    DescriptionCustomFlex is a custom-made, thin, foldable medical-grade silicone prosthetic iris that can be sized and colored for individual patients.
    FDA statusReferenced in the FDA Summary of Safety and Effectiveness Data (PMA P170039); described as an FDA‑approved marketed artificial iris prosthesis in the SSED.
    Clinical useUsed to treat congenital and traumatic aniridia and other iris defects; can be implanted endocapsularly, in the sulcus, or with scleral fixation.
    Endocapsular implantation — definition and outcome association
    DefinitionPlacement of the artificial iris within the capsular bag (endocapsular space) during implantation.
    Associated outcomesIn reported series, endocapsular implantation was associated with fewer severe post-operative complications and high patient satisfaction (94.4% would have procedure again).
    Observed complicationsMild/self-limiting complications reported included elevated IOP (42.1%), cystoid macular edema (15.8%), persistent uveitis (15.8%) and minor prosthesis vaulting (15.7%); moderate/severe complications were less frequent.
    CustomFlex™ Artificial Iris — reference to FDA SSED (PMA P170039)
    Regulatory referenceCustomFlex™ Artificial Iris is referenced in the FDA Summary of Safety and Effectiveness Data (PMA P170039).
    Source documentClinical SSED: CustomFlex™ Artificial Iris, Premarket Approval Application (PMA) P170039, FDA; referenced in policy bibliography.
    ImplicationFDA SSED citation indicates the CustomFlex device has publicly available safety and effectiveness documentation associated with PMA P170039.